WORCESTER, Mass., May 7, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced that on May 6, 2010 the Company was notified by the NASDAQ staff that the Company is not in compliance with the $1.00 minimum bid price requirement in Listing Rule 5550(a)(2) (the Company remains in compliance with all other listing maintenance requirements). As a result, the Company’s common stock is subject to delisting from the NASDAQ Capital Market (in which event the stock will be eligible to trade on the OTC Bulletin Board (after approval of a market maker application to register and quote the security)).
